Crenolanib for Treating FLT3 Mutated Proliferative Disorders
AssigneeArog Pharmaceuticals, Inc.
InventorVinay K. Jain
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of crenolanib, in a pharmaceutically acceptable salt form for the treatment of FLT3 mutated proliferative disorders driven by constitutively activated mutant FLT3, and to a method of treatment of warm-blooded animals, preferably humans, in which a therapeutically effective dose of crenolanib is administered to an animal suffering from said disease or condition:
Claims41
A method for treating a FLT3 mutated proliferative disorder in a patient that comprises administering to the patient a therapeutically effective amount of crenolanib or a pharmaceutically acceptable salt thereof.
A method for treating a patient suffering from a proliferative disease comprising:
- identifying the patient in need of therapy for the proliferative disease;
- and
- administering to the patient in need of such treatment a therapeutically effective amount of Crenolanib or a salt thereof, wherein the cell proliferative disorder is characterized by deregulated FLT3 receptor tyrosine kinase activity, wherein the proliferative disease is selected from at least one of a leukemia, myeloma, myeloproliferative disease, myelodysplastic syndrome, idiopathic hypereosinophilic syndrome (HES), bladder cancer, breast cancer, cervical cancer, CNS cancer, colon cancer, esophageal cancer, head and neck cancer, liver cancer, lung cancer, nasopharyngeal cancer, neuroendocrine cancer, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, salivary gland cancer, small cell lung cancer, skin cancer, stomach cancer, testicular cancer, thyroid cancer, uterine cancer, and hematologic malignancy.
A method for treating a patient suffering from leukemia comprising:
- obtaining a sample from the patient suspected of having leukemia;
- determining from the patient sample that the patient has a deregulated FLT3 receptor tyrosine kinase;
- and
- administering to the patient in need of such treatment a therapeutically effective amount of Crenolanib or a salt thereof, wherein the leukemia is characterized by deregulated FLT3 receptor tyrosine kinase activity.
A method for specifically inhibiting a deregulated receptor tyrosine kinase comprising:
- obtaining a patient sample;
- determining which receptor tyrosine kinases are deregulated;
- and
- administering to a mammal in need of such treatment a therapeutically effective amount of crenolanib or a salt thereof, wherein the deregulated receptor tyrosine kinase is a FLT3 receptor tyrosine kinase.
A method for treating a patient with a proliferative disease comprising:
- obtaining a sample from the patient;
- determining if the patient that has become resistant to prior tyrosine kinase inhibitors or chemotherapy;
- and
- administering a therapeutically effective amount of Crenolanib or a salt thereof to overcome the resistance to the prior protein tyrosine kinase inhibitors.
Dependencies are inferred from the claim text.